PMCTPharmaCountry
    Home

Regulatory Updates

FDA, EMA, TGA and global regulatory developments

#Monoclonal Antibody ×

UPDATED
Regulatory Updates
Sep 18, 2026•1 min read
FDA Grants Priority Approval for AstraZeneca's IMFINZI (Durvalumab) BLA761069
The FDA approved AstraZeneca’s IMFINZI (durvalumab) under BLA761069, with priority review for efficacy and ongoing labeling updates through 2026.